Erlotinib, afatinib, and gefitinib are quinazolamine-based small-molecule inhibitors of EGFR, which have been approved for the treatment of metastatic NSCLC [18,19,20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.